Literature DB >> 10717103

Chemoradiation: A Superior Alternative for the Primary Management of Esophageal Carcinoma.

.   

Abstract

There have been no randomized studies of esophagectomy versus chemoradiation as primary management of esophageal cancer. Review of the literature indicates esophagectomy alone has limited applicability, significant morbidity, higher mortality, and a lesser chance for cure than chemoradiation for patients with squamous cell cancer of the esophagus. The majority of patients with esophageal cancer have disease extending through the esophageal wall or nodal involvement and the prognosis for such patients treated by esophagectomy alone is quite poor, with 5-year survival rate of 10% or less. Recent studies indicate 5-year survival rates with chemoradiation is 20% to 25%. Local failure rates are similar with chemoradiation versus esophagectomy, but swallowing function is superior with chemoradiation. Salvage surgery is possible following chemoradiation for the small percentage of patients who have local-only failure. Chemoradiation is preferred to esophagectomy for patients with squamous cell cancer of the esophagus, and offers significant palliation and the chance for cure for patients with adenocarcinoma of the esophagus as well.

Entities:  

Year:  1994        PMID: 10717103     DOI: 10.1053/SRAO00400157

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  4 in total

1.  Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue.

Authors:  Ichinosuke Hyodo
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

2.  Update: modern approaches to the treatment of localized esophageal cancer.

Authors:  James Welsh; Arya Amini; Anna Likhacheva; Jeremy Erasmus J; Daniel Gomez; Marta Davila; Reza J Mehran; Ritsuko Komaki; Zhongxing Liao; Wayne L Hofstetter; Jeffrey Lee H; Manoop S Bhutani; Jaffer A Ajani
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

Review 3.  Comparison of different treatments for unresectable esophageal cancer.

Authors:  C E Reed
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

4.  Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.

Authors:  Maria Wolf; Franz Zehentmayr; Maximilian Niyazi; Ute Ganswindt; Wolfgang Haimerl; Michael Schmidt; Dieter Hölzel; Claus Belka
Journal:  Strahlenther Onkol       Date:  2010-06-24       Impact factor: 3.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.